CA2878867C - Dosing regimen for janus kinase (jak) inhibitors - Google Patents

Dosing regimen for janus kinase (jak) inhibitors Download PDF

Info

Publication number
CA2878867C
CA2878867C CA2878867A CA2878867A CA2878867C CA 2878867 C CA2878867 C CA 2878867C CA 2878867 A CA2878867 A CA 2878867A CA 2878867 A CA2878867 A CA 2878867A CA 2878867 C CA2878867 C CA 2878867C
Authority
CA
Canada
Prior art keywords
dose
ring
administration
compound
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2878867A
Other languages
English (en)
French (fr)
Other versions
CA2878867A1 (en
Inventor
Andrea J. GONZALES
Sallie B. COSGROVE
Phyllis B. MALPAS
Michael Rolf STEGEMANN
Wendy Turner COLLARD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zoetis Services LLC
Original Assignee
Zoetis Services LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48901189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2878867(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis Services LLC filed Critical Zoetis Services LLC
Publication of CA2878867A1 publication Critical patent/CA2878867A1/en
Application granted granted Critical
Publication of CA2878867C publication Critical patent/CA2878867C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
CA2878867A 2012-07-20 2013-07-18 Dosing regimen for janus kinase (jak) inhibitors Active CA2878867C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261674289P 2012-07-20 2012-07-20
US61/674,289 2012-07-20
US201361815803P 2013-04-25 2013-04-25
US61/815,803 2013-04-25
PCT/US2013/051015 WO2014015107A1 (en) 2012-07-20 2013-07-18 Dosing regimen for janus kinase (jak) inhibitors

Publications (2)

Publication Number Publication Date
CA2878867A1 CA2878867A1 (en) 2014-01-23
CA2878867C true CA2878867C (en) 2018-01-09

Family

ID=48901189

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2878867A Active CA2878867C (en) 2012-07-20 2013-07-18 Dosing regimen for janus kinase (jak) inhibitors

Country Status (25)

Country Link
US (1) US9522151B2 (2)
EP (1) EP2874630B1 (2)
JP (2) JP6022063B2 (2)
KR (2) KR20170034949A (2)
CN (2) CN108354938A (2)
AU (1) AU2013292547B2 (2)
BR (1) BR112015000808A2 (2)
CA (1) CA2878867C (2)
CY (1) CY1121436T1 (2)
DK (1) DK2874630T3 (2)
ES (1) ES2707627T3 (2)
HK (2) HK1209314A1 (2)
HR (1) HRP20182088T1 (2)
HU (1) HUE042771T2 (2)
IN (1) IN2015DN00370A (2)
LT (1) LT2874630T (2)
MX (1) MX360857B (2)
NZ (1) NZ703152A (2)
PL (1) PL2874630T3 (2)
PT (1) PT2874630T (2)
RS (1) RS58242B1 (2)
SI (1) SI2874630T1 (2)
SM (1) SMT201900044T1 (2)
WO (1) WO2014015107A1 (2)
ZA (1) ZA201500134B (2)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4327812A4 (en) * 2021-04-22 2025-01-15 Shenzhen Chipscreen Biosciences Co., Ltd. PHARMACEUTICAL COMPOSITION CONTAINING A SELECTIVE JAK3/JAK1/TBK1 INHIBITOR AND ITS MEDICAL USE

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP201606600B (en) 2013-02-22 2017-01-10 Pfizer Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus- related kinases (jak)
WO2016024185A1 (en) 2014-08-12 2016-02-18 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
SG10201913990RA (en) 2015-10-16 2020-03-30 Abbvie Inc PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10973913B2 (en) 2016-02-16 2021-04-13 Washington University JAK inhibitors and uses thereof
CN107098908B (zh) * 2016-02-23 2021-01-08 欣凯医药科技(上海)有限公司 一种吡咯并嘧啶类化合物的制备方法和应用
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
MX2021008984A (es) * 2019-01-30 2021-09-08 Felicamed Biotechnology Co Ltd Inhibidor jak y metodo de preparacion del mismo.
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
MX2023007150A (es) 2020-12-18 2023-09-04 Boehringer Ingelheim Animal Health Usa Inc Compuestos de pirazol que contienen boro, composiciones que los comprenden, métodos y usos de los mismos.
AU2022239128B2 (en) * 2021-03-16 2024-09-05 Hk Inno.N Corporation Novel salts of heterocyclic compound as protein kinase inhibitor and uses thereof
WO2024259429A2 (en) * 2023-06-16 2024-12-19 The University Of Chicago Methods and compositions for pharmaceutically relevant interactions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK286640B6 (sk) 1998-06-19 2009-03-05 Pfizer Products Inc. Pyrol [2,3-d] pyrimidínová zlúčenina, jej použitie na výrobu liečiva, farmaceutická kompozícia s jej obsahom, použitie jej kombinácie s ďalšími činidlami a súpravy s jej obsahom na výrobu liečiva
KR101335843B1 (ko) 2008-08-20 2013-12-02 조에티스 엘엘씨 피롤로[2,3-ｄ]피리미딘 화합물

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4327812A4 (en) * 2021-04-22 2025-01-15 Shenzhen Chipscreen Biosciences Co., Ltd. PHARMACEUTICAL COMPOSITION CONTAINING A SELECTIVE JAK3/JAK1/TBK1 INHIBITOR AND ITS MEDICAL USE

Also Published As

Publication number Publication date
HK1209314A1 (en) 2016-04-01
MX360857B (es) 2018-11-20
HRP20182088T1 (hr) 2019-02-08
KR20170034949A (ko) 2017-03-29
AU2013292547B2 (en) 2017-05-04
ES2707627T3 (es) 2019-04-04
PL2874630T3 (pl) 2019-04-30
CY1121436T1 (el) 2020-05-29
CA2878867A1 (en) 2014-01-23
WO2014015107A1 (en) 2014-01-23
AU2013292547A1 (en) 2015-01-22
CN104470525A (zh) 2015-03-25
NZ703152A (en) 2016-03-31
BR112015000808A2 (pt) 2017-06-27
EP2874630A1 (en) 2015-05-27
EP2874630B1 (en) 2018-12-05
JP2017019816A (ja) 2017-01-26
SI2874630T1 (sl) 2019-04-30
JP6022063B2 (ja) 2016-11-09
CN108354938A (zh) 2018-08-03
SMT201900044T1 (it) 2019-02-28
US9522151B2 (en) 2016-12-20
LT2874630T (lt) 2019-02-11
HK1252083A1 (zh) 2019-05-17
MX2015000871A (es) 2015-05-07
DK2874630T3 (en) 2019-01-28
HUE042771T2 (hu) 2019-07-29
RS58242B1 (sr) 2019-03-29
US20150126535A1 (en) 2015-05-07
JP2015522620A (ja) 2015-08-06
ZA201500134B (en) 2016-08-31
PT2874630T (pt) 2019-01-31
KR20150028299A (ko) 2015-03-13
IN2015DN00370A (2) 2015-06-12

Similar Documents

Publication Publication Date Title
CA2878867C (en) Dosing regimen for janus kinase (jak) inhibitors
US11318151B2 (en) Compound pharmaceutical composition for treating skin inflammatory diseases
EP4028007B1 (en) Treatment of hidradenitis suppurativa with a jak inhibitor
US20190314382A1 (en) Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases
Morini et al. Development of an oral treatment that rescues gait ataxia and retinal degeneration in a phenotypic mouse model of familial dysautonomia
ES3059530T3 (en) Jak1 pathway inhibitors for the treatment of prurigo nodularis
CN119112900A (zh) 抗胶质母细胞瘤的药物组合物及其应用
CN118984704A (zh) 治疗卵巢癌的药物组合和方法
US20230293544A1 (en) Methods, dosage regimens, and compositions for treating hidradenitis
US20250002492A1 (en) Compositions of folate absorption inhibitors and methods thereof
US20230416244A1 (en) Imidazoquinoline compound having anti-inflammatory, antifugal, antiparasitic, and anticancer activity
WO2017160813A1 (en) Compositions and methods for treating compulsive-like behavior in a subject
HK40115079A (zh) 用於治疗汗腺炎的方法、剂量方案和组合物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150109

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250612

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250612